Canadian Sec - Free Realtime Quote CAD

InnoCan Pharma Corporation (INNO.CN)

0.1600

-0.0100

(-5.88%)

As of 9:49:15 AM EDT. Market Open.

TSX Penny Stocks To Watch In May 2025

With Canada's election now behind it, one source of uncertainty has been removed, allowing policymakers to focus on trade and economic issues. As the market adjusts to these changes, investors are keenly watching for opportunities that align with evolving fiscal policies and potential interest rate cuts. Penny stocks, though a somewhat outdated term, still represent smaller or newer companies that can offer value when backed by strong financials. We've identified three such stocks that may...

Simply Wall St. 5 days ago

INNPF

QIFTF

EQTRF
Innocan Pharma First Granted Patent in Mexico for its Topical Pain Relief

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the Mexican patent office has issued a notice of allowance for the Company's patent application covering its proprietary topical pain-relief technology.

CNW Group 8 days ago

INNPF

INN

INN-PE
Innocan Pharma Announces Closing of Private Placement

Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the "Offering") of units of the Company (the "Units"), pursuant to which the Company issued 1,193,551 Units at a price of $0.18 per Unit (the "Offering Price") for aggregate gross proceeds of $214,839.

CNW Group 29 days ago

INN

INN-PE

INN-PF
Innocan Pharma Broadens Intellectual Property Coverage for its Liposomal CBD Injection Across Asia and Announces Private Placement of Units

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that a divisional application for its Chinese (CN) liposome-based CBD technology patent was filed.

CNW Group last month

INNPF

INN

INN-PE
Innocan Pharma Reports Full Year 2024 Results with Revenues more than Doubling to US $29.4 million

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its audited financial consolidated results for the year ended December 31, 2024.

CNW Group last month

INNPF

INN

INN-PE
InnoCan Pharma And 2 Other TSX Penny Stocks With Growth Potential

As the Canadian market navigates trade uncertainties and inflation concerns, investors are seeking opportunities that balance growth potential with resilience. Penny stocks, though a somewhat outdated term, continue to capture attention as they often represent smaller or newer companies with the potential for significant value appreciation. By focusing on those with strong financials and a clear path to growth, investors can uncover promising opportunities within this segment of the market.

Simply Wall St. last month

NMYSF

CCARF

INNPF
Innocan Pharma Announces Closing of Debenture Unit Offering to its Largest Shareholder, Tamar Innovest Limited

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its previously announced non-brokered private placement offering of a debenture unit of the Company (the "Debenture Unit") to its largest shareholder, Tamar Innovest Ltd. ("Tamar Innovest") for gross proceeds of US $1,000,000 (the "Offering").

CNW Group 2 months ago

INN

INN-PE

INN-PF
Innocan Pharma Announces Private Placement Offering of a Debenture Unit to its Largest Shareholder, Tamar Innovest

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete an offering of a debenture unit of the Company (the "Debenture Unit") to its largest shareholder, Tamar Innovest Ltd. ("Tamar Innovest") for gross proceeds of US $1,000,000 (the "Offering").

CNW Group 2 months ago

INN

INN-PE

INN-PF
TSX Penny Stocks Under CA$60M Market Cap: Discovering Promising Opportunities

As the Canadian TSX index experiences a modest 3% rise amidst stabilizing yields and contained inflation, investors are increasingly looking for opportunities in smaller, potentially high-growth segments of the market. Penny stocks, while an older term, continue to capture attention due to their ability to represent smaller or newer companies with significant upside potential. By focusing on those with strong financials and clear growth paths, investors can uncover promising opportunities...

Simply Wall St. 2 months ago

FRACF

MJGCF

INNPF
Innocan Pharma's Liposomal CBD Injection Shows Breakthrough Pain Relief in Elderly Donkey with Osteoarthritis

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful outcome from the compassionate treatment of a female donkey with its innovative liposomal CBD injection (LPT-CBD). Innocan's innovative therapy provided quick and sustained pain relief, significantly improving mobility in an elderly female donkey suffering from osteoarthritis.

CNW Group 2 months ago

INNPF

INN

INN-PE
Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that its subsidiary, BI Sky Global (BI), successfully completed the Human Repeated Insult Patch Test (HRIPT) for Sensitization and Irritation Testing, ensuring the safety of its cosmetic products. HRIPT is the personal care industry's standard safety test for cosmetic, OTC drug, and topical medical devices.

CNW Group 3 months ago

INN

INN-PE

INN-PF
TSX Penny Stock Picks For January 2025

As we step into 2025, the Canadian market is navigating a landscape shaped by new U.S. policies on energy, immigration, tariffs, and technology. With the TSX index showing resilience since Inauguration Day and potential rate adjustments by the Bank of Canada on the horizon, investors are keenly observing these developments. Amidst this backdrop, penny stocks—often representing smaller or emerging companies—remain a niche yet intriguing investment area for those seeking growth opportunities...

Simply Wall St. 3 months ago

INNPF

MGPHF

CPCPF
FDA's Center for Veterinary Medicine Grants Innocan Pharma a Fee Waiver for 2025

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product for the second consecutive year.

CNW Group 4 months ago

INN

INN-PE

INN-PF
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of C$635,444.60

Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the "Offering") of units of the Company (the "Units"), pursuant to which the Company issued 3,177,223 Units at a price of C$0.20 per Unit (the "Offering Price") for aggregate gross proceeds of $635,444.60.

CNW Group 4 months ago

INN

INN-PE

INN-PF
InnoCan Pharma Leads Our Trio Of TSX Penny Stock Picks

The Canadian market has experienced some pullback recently, driven by political uncertainty and profit-taking after a strong year of growth. Despite this volatility, the underlying economic fundamentals remain robust, providing a landscape where smaller companies can thrive. Penny stocks, though often overlooked due to their historical connotations, continue to offer intriguing opportunities for investors seeking value and growth potential in financially sound enterprises.

Simply Wall St. 4 months ago

NBMFF

NNOMF

INNPF
Innocan Pharma Announces Private Placement of Units

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete a non-brokered private placement of up to [3,500,000] units of the Company (the "Units") at a price of [C$0.20] per Unit for gross proceeds up to C$700,000 plus 15% over allotment options (the "Offering"). The Offering is expected to close on or around December 31, 2024.

CNW Group 4 months ago

INNPF

INN

INN-PE
Innocan Pharma Provides its Annual "State of Research and Development" Update for 2024

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and an owner of a proprietary intellectual property portfolio, is pleased to share its annual "State of Research and Development" update for 2024. This year, the Company achieved significant milestones in advancing research and development for its drug delivery platforms as well as its intellectual

CNW Group 4 months ago

INNPF

INN

INN-PE
3 TSX Penny Stocks With Market Caps Over CA$20M To Watch

The Canadian market is experiencing strong momentum as it heads into 2025, supported by a resilient consumer base, rising corporate profits, and the beginning of a rate-cutting cycle. Amidst this positive backdrop, investors may find opportunities in areas that have traditionally been overlooked, such as penny stocks. While the term "penny stock" might seem outdated, these smaller or newer companies can still offer significant growth potential when backed by solid financials and fundamentals.

Simply Wall St. 5 months ago

ZMDTF

TNREF

INNPF
Innocan Pharma Announces Encouraging Results from a Safety Assessment Study of LPT-CBD on Minipigs

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to report positive results from a basic safety assessment study, evaluating LPT-CBD administered as a single injection in Göttingen minipigs.

CNW Group 5 months ago

INNPF

INN

INN-PE
Innocan Pharma Reports Third Quarter 2024 Financial Results

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its consolidated financial results for the three and nine-month periods ended September 30, 2024.

CNW Group 5 months ago

INN

INN-PE

INN-PF

Performance Overview

Return	INNO.CN	S&P/TSX Composite index (^GSPTSE)
YTD	-23.81%	+3.90%
1-Year	-43.86%	+15.00%
3-Year	-70.91%	+27.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

InnoCan Pharma Corporation (INNO.CN)

TSX Penny Stocks To Watch In May 2025

Innocan Pharma First Granted Patent in Mexico for its Topical Pain Relief

Innocan Pharma Announces Closing of Private Placement

Innocan Pharma Broadens Intellectual Property Coverage for its Liposomal CBD Injection Across Asia and Announces Private Placement of Units

Innocan Pharma Reports Full Year 2024 Results with Revenues more than Doubling to US $29.4 million

InnoCan Pharma And 2 Other TSX Penny Stocks With Growth Potential

Innocan Pharma Announces Closing of Debenture Unit Offering to its Largest Shareholder, Tamar Innovest Limited

Innocan Pharma Announces Private Placement Offering of a Debenture Unit to its Largest Shareholder, Tamar Innovest

TSX Penny Stocks Under CA$60M Market Cap: Discovering Promising Opportunities

Innocan Pharma's Liposomal CBD Injection Shows Breakthrough Pain Relief in Elderly Donkey with Osteoarthritis

Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone

TSX Penny Stock Picks For January 2025

FDA's Center for Veterinary Medicine Grants Innocan Pharma a Fee Waiver for 2025

Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of C$635,444.60

InnoCan Pharma Leads Our Trio Of TSX Penny Stock Picks

Innocan Pharma Announces Private Placement of Units

Innocan Pharma Provides its Annual "State of Research and Development" Update for 2024

3 TSX Penny Stocks With Market Caps Over CA$20M To Watch

Innocan Pharma Announces Encouraging Results from a Safety Assessment Study of LPT-CBD on Minipigs

Innocan Pharma Reports Third Quarter 2024 Financial Results

Performance Overview